Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Share-based Compensation (2023 - 2025)

Metagenomi (MGX) has disclosed Share-based Compensation for 3 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 21.04% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.9 million through Dec 2025, down 26.85% year-over-year, with the annual reading at $11.9 million for FY2025, 26.85% down from the prior year.
  • Share-based Compensation for Q4 2025 was $2.7 million at Metagenomi, down from $3.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $5.1 million in Q1 2024, with the low at $529000.0 in Q1 2023.
  • Average Share-based Compensation over 3 years is $2.9 million, with a median of $3.1 million recorded in 2025.
  • The sharpest move saw Share-based Compensation skyrocketed 855.95% in 2024, then crashed 42.1% in 2025.
  • Over 3 years, Share-based Compensation stood at $2.5 million in 2023, then soared by 38.19% to $3.4 million in 2024, then dropped by 21.04% to $2.7 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $2.7 million, $3.0 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.